Publications

Morphine glucuronidation

Knibbe C.A., Krekels E.H., Anker J.N.v.d., Jongh J.d., Santen G.W., Dijk M.v., Simons S.H., Lingen R.A.v., Jacqz-Aigrain E.M., Danhof M. and Tibboel D., Morphine glucuronidation in preterm neonates, infants and children younger than 3 years, Clin Pharmacokinet, 48(6): 371-385, 2009. [Link to publication]

Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats

Bender G., Gosset J., Florian J., Tan K., Field M., Marshall S., Jongh J.d., Bies R. and Danhof M., Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: application of simulation to preclinical PK-PD study design, Pharm Res, 26(10): 2259-2269, 2009. [Link to publication]

Pharmacokinetics of a granisetron transdermal system

Howell J., Smeets J., Drenth H.J.,  and Gill D., Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy- induced nausea and vomiting, J Oncol Pharm Pract, 20: 20, 2009. [Link to publication]

Effect of altered AGP plasma binding on heart rate changes

Steeg T.J.v., Krekels E.H., Freijer J., Danhof M.  and Lange E.C.d., Effect of altered AGP plasma binding on heart rate changes by S(-)-propranolol in rats using mechanism-based estimations of in vivo receptor affinity (K(B,vivo)), J Pharm Sci, 17: 17, 2009. [Link to publication]

Influence of plasma protein binding on pharmacodynamics

Steeg T.J.v., Boralli V.B., Krekels E.H., Slijkerman P., Freijer J., Danhof M. and Lange E.C.d., Influence of plasma protein binding on pharmacodynamics: Estimation of in vivo receptor affinities of beta blockers using a new mechanism-based PK-PD modelling approach, J Pharm Sci., 98(10): 3816-3828., 2009. [Link to publication]

Explaining variability in tacrolimus pharmacokinetics

Press R.R., Ploeger B.A., Hartigh J. d, Straaten T.v.d., Pelt J.v., Danhof M., Fijter J.W.d and Guchelaar H.J., Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients, Ther Drug Monit., 31(2): 187-197., 2009. [Link to publication]

Reversal of neuromuscular blockade

Ploeger B.A., Smeets J., Strougo A., Drenth H.J., Ruigt G., Houwing N.  and Danhof M., Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex, Anesthesiology., 110(1): 95-105., 2009. [Link to publication]

Washout and delayed start designs for identifying disease modifying effects

Ploeger B.A. and Holford N.H., Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis, Pharm Stat., 8(3): 225-238., 2009. [Link to publication]

Incorporating receptor theory

Ploeger B.A., Graaf P.H.v.d and Danhof M., Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling, Drug Metab Pharmacokinet., 24(1): 3-15., 2009. [Link to publication]

Changes in GABAA receptor properties in amygdala kindled animals

Liefaard L.C., Ploeger B.A., Molthoff C.F., Jong H.W.d, Dijkstra J., Weerd L.v.d., Lammertsma A.A., Danhof M. and Voskuyl R.A., Changes in GABAA receptor properties in amygdala kindled animals: in vivo studies using [11C]flumazenil and positron emission tomography, Epilepsia., 50(1): 88-98., 2009.  [Link to publication]